ライフサイエンスコーパス: ADP receptor

1 ecreted ADP acting on the G alpha(i2)-linked ADP receptor.

2 at platelets express at least one additional ADP receptor.

3 an blood platelets has been identified as an ADP receptor.

4 a release of ADP from Ap3A and activation of ADP receptors.

5 n by antagonizing the adenosine-diphosphate (ADP) receptor.

6 t the activation of other GPCRs, such as the ADP receptors and protease-activated receptors, can also

7 eversibly with aggregin (100kDa), a putative ADP receptor, and induces platelet shape change and aggr

8 Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversi

9 id-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events d

10 a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quick

11 ction through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both t

12 However, experiments with specific ADP receptor antagonists and platelets from knockout mic

13 roaches to many cardiovascular diseases, and ADP receptor antagonists are in widespread clinical use.

14 ADP receptor antagonists are widely used to treat cardio

15 ADP receptor antagonists shifted the concentration-respo

16 Adenosine diphosphate (ADP) scavengers or ADP receptor antagonists shifted the concentration-respo

17 Blockade of both ADP receptors at 3000 s(-1) with ARMX plus A3P5P further

18 Finally, by using ADP receptor blockade we confirm that NPP4 mediates plat

19 rs of premature discontinuation or switch of ADP receptor blockers and its association with serious a

20 AR-C66096, a P2TAC (platelet ADP receptor coupled to inhibition of adenylate cyclase)

21 (GTP)-binding protein G(q), and the platelet ADP receptor coupled to inhibition of adenylyl cyclase (

22 could be mimicked by coactivation of two non-ADP receptors coupled to Gi and Gq, neither of which can

23 ceptors: the platelet adenosine diphosphate (ADP) receptor coupled to stimulation of phospholipase C

24 he platelet P2Y(1)(2) adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggreg

25 d to tissue damage through activation of ATP/ADP receptors followed by directional process extension

26 demonstrate that the recently cloned P2Y(12) ADP receptor (G(i)-coupled ADP receptor) is involved in

27 investigated whether defects in the P2Y(12) ADP receptor gene (P2RY12) contribute to the bleeding te

28 sults demonstrate that P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition i

29 strate the presence of two distinct platelet ADP receptors in addition to the P2X receptor: one coupl

30 show the expression of P2RY1, but not other ADP receptors, in EC with a pattern similar to VEGFR2.

31 age, sex, baseline aspirin use, and type of ADP receptor inhibitor (clopidogrel versus prasugrel/tic

32 ave compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myo

33 particular when patients use platelet P2Y12 ADP receptor inhibitors.

34 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Trea

35 py at 228 US hospitals in the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Trea

36 Anticoagulants, aspirin, and ADP-receptor inhibitors were permitted in this study.

37 suggesting that inside-out signaling through ADP receptors is necessary for this event.

38 ly cloned P2Y(12) ADP receptor (G(i)-coupled ADP receptor) is involved in this pathway, and that the

39 gh nPKCeta was phosphorylated within 30 s by ADP receptors, it was also dephosphorylated by activated

40 Additional ADP receptors linked to Galpha(i) have been described bu

41 , and that the P2Y(1) receptor (G(q)-coupled ADP receptor) may play a less significant role.

42 gically distinct from the well-characterized ADP receptors of these cells.

43 Both P2Y(1) and P2Y(12) are ADP receptors on human platelets and are essential for A

44 existence of two distinct G protein-coupled ADP receptors on platelets, one coupled to phospholipase

45 trated earlier the existence of two distinct ADP receptors on platelets, one coupled to phospholipase

46 of multiple types of adenosine diphosphate (ADP) receptors, one coupled to ligand-gated cation chann

47 agents that block the adenosine diphosphate (ADP) receptor, or regulate platelet free cytosolic calci

48 ingle nucleotide polymorphisms (SNPs) within ADP receptor (P2RY1, P2RY12) and cytochrome P450 isoenzy

49 (protease-activated receptors, PARs) and the ADP receptor P2RY12 (purinergic receptor P2Y G protein-c

50 The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein

51 The ADP receptor P2Y(12) belongs to the superfamily of G pro

52 cate that combinations of antagonists of the ADP receptors P2Y(12) and P2Y(1) are effective inhibitor

53 it was shown that adenosine 5'-diphosphate (ADP) receptors P2Y(12) and P2Y(1) are both important in

54 cking the adenylyl cyclase--coupled platelet ADP receptor (P2Y(12)) on wild-type platelets with a sel

55 e lacking G(alpha)(i2), which couples to the ADP receptor, P2Y12, exhibit reduced Rap1 activation in

56 demonstrate that activation of the platelet ADP receptor, P2Y12, severely blunts the inhibitory effe

57 tes downstream of the adenosine diphosphate (ADP) receptor, P2Y12, a target of antithrombotic therapy

58 ADP receptors regulate arrestin recruitment to PAR4, bec

59 The second ADP receptor required for aggregation (variously called

60 The molecular identity of the ADP receptor(s) in human platelets, however, is still un

61 with studies of human platelets treated with ADP receptor-selective inhibitors, indicates that ADP-st

62 ionic conditions, oscillates in response to ADP receptor stimulation due to activation by both IP3 a

63 otein coupling domains of the human platelet ADP receptor, we constructed a chimeric hemagglutinin-ta

64 : the coinhibition of adenosine diphosphate (ADP) receptors with collagen receptors further decreased